Jack Cox is a seasoned professional with over 25 years of experience in the pharmaceutical, biotech, and specialty pharmacy sectors, currently serving as the Senior Director of Value Communication and Contract Strategy for BioPharm and Insulin at Novo Nordisk. In this pivotal role, Jack leads...
Jack Cox is a seasoned professional with over 25 years of experience in the pharmaceutical, biotech, and specialty pharmacy sectors, currently serving as the Senior Director of Value Communication and Contract Strategy for BioPharm and Insulin at Novo Nordisk. In this pivotal role, Jack leads the development and execution of pricing and contract strategies that drive market access for both inline and pipeline assets. His expertise is particularly pronounced in navigating the complexities of orphan and ultra-orphan drug launches, where he has successfully implemented innovative distribution model strategies that enhance patient access while ensuring sustainable business growth.
At Novo Nordisk, Jack is instrumental in overseeing evidence generation initiatives that support market access efforts, ensuring that the value proposition of their products is effectively communicated to stakeholders. His strategic vision is complemented by a deep understanding of specialty pharmacy dynamics, biosimilars, and the unique challenges associated with diabetes management. Jack’s leadership is characterized by a transformational approach, where he not only drives growth initiatives but also fosters collaboration across cross-functional teams to align on objectives and optimize outcomes.
In addition to his strategic responsibilities, Jack is passionate about mentoring emerging leaders in the industry, sharing his insights on market access and the intricacies of contract negotiations. His ability to adapt and thrive in both startup environments and during organizational realignments has solidified his reputation as a key player in the pharmaceutical landscape, making him a valuable asset to Novo Nordisk and the broader healthcare community.
